The myMatrixx clinical pharmacy team has released an updated version of their Position Paper regarding COVID-19 Vaccination, Treatment and Coverage under Workers’ Compensation. Originally released in February, the updated October 2021 version contains new information around treatments of interest, including Merck’s antiviral pill, molnupiravir. There are also updates regarding booster shots and guidelines and resources for prioritizing safety for companies returning to traditional job sites.
Carried over from the original version are an overview of the cost of the vaccine, associated administration fees, reimbursement guidelines, and formulary considerations, particularly as they may apply to the workforce. You can view the full position paper and find the latest updates on the myMatrixx COVID-19 resources page.